Gene Editing Markets 2027–2031

Gene Editing Markets: Market Forecast, Competitive Landscape, Technology and Partnering Opportunities, 2027–2031 (October 2026)

Global forecasts by application, technology, editing setting, customer and product, for 14 countries and regions, with 56 company profiles.

See the Table of Contents. GET the Free Sample of this Report.

Many organizations subscribe to all or some of our reports. You may already have free access to this report. FIND out Here.

Our Take

Gene editing is moving from research tool to approved medicine. The market grows from $11.4 billion in 2026 to $23.8 billion in 2031, at 15.9% a year. Base, prime and epigenetic editors take 44% of the new spending, editing moves into the patient, and therapies, services and agriculture overtake the research reagents that built the field.

Market Size 2026: USD $11.4B Market Size 2031: USD $23.8B CAGR: 15.9%

Situation Analysis: what is really happening

• Beyond the CRISPR cut. Base editing grows 28.6% a year to $3,808 million and prime editing 38.4% a year to $2,023 million. CRISPR-Cas Nuclease remains the largest technology at $7,638 million in 2026, but its share falls from 67.0% to 57.0%.
• Editing moves into the patient. In vivo editing grows 27.9% a year to $4,879 million, rising from 12.5% to 20.5% of the market. The FDA accepted Intellia's lonvo-z, the first in vivo CRISPR therapy with Phase 3 results, for priority review with a target date of 10 March 2027.
• Therapies take off. Gene Therapy grows 26.0% a year and Cell Therapy 23.0%; together they take 40% of the growth. The FDA approved Casgevy for children aged 2 and older, and its second-quarter 2026 revenue rose to $76.4 million.
• Services lead the products. Services grow 19.0% a year to $8,449 million and take 40% of new spending, as developers outsource guide RNA, editing and manufacturing.
• Safety and money still matter. A patient died after a severe liver event in Intellia's ATTR Phase 3 trial, and Sangamo filed for Chapter 11 before Lilly bought its platform technologies for $50 million.
• Agriculture and China grow fast. Agriculture & Plants grows 18.0% a year as the EU's new genomic techniques regulation was approved, and China is the fastest-growing major country at 18.6% a year.

Company Analysis: who is positioned, who is exposed

• CRISPR Therapeutics and Vertex: Casgevy is approved in 39 countries, and CRISPR Therapeutics' in vivo ANGPTL3 editing cut triglycerides by about 55%.
• Intellia Therapeutics: Lonvo-z is under FDA priority review, while its ATTR programme recovers from a patient death after a severe liver event.
• Beam Therapeutics and Prime Medicine: Beam plans a BLA for risto-cel and has $1.2 billion in cash; Prime won its licence arbitration with Beam and is taking an in vivo prime editor for AATD into the clinic.
• Eli Lilly: Owns Verve, bought Sangamo's platforms and agreed to buy Kelonia, making it the most active large company in editing and delivery.
• Thermo Fisher, Merck KGaA, IDT, GenScript and Synthego: Supply the guide RNAs, enzymes, kits and services the whole field depends on.
• Genus, Corteva and Pairwise: Lead gene-edited livestock and crops, led by Genus's PRRS-resistant pig.

In all, 56 company profiles, each one to two pages with a fact box covering website, headquarters, ownership, revenue, employees and key products.

Questions this report answers

• How fast will base, prime and epigenetic editing take share from CRISPR-Cas nucleases?
• How large can in vivo editing become once the first therapies are approved?
• Which applications, customers and products will add the most new spending?
• How will regulators and payers handle one-time and individualised editing therapies?
• Who are the leading developers and suppliers, and what are gene editing companies selling for?
• How large is each country market, and how fast is China growing?

What's inside

• 384 pages, 24 chapters, 56 tables and 56 figures
• Forecasts for 2027–2031 from a 2026 base year, by application, technology, editing setting, customer and product, for 14 countries and regions
• Approved therapies and clinical pipeline, CRISPR diagnostics, agriculture and animal editing, technology landscape, tools, reagents and services
• Regulation and reimbursement, intellectual property, litigation and pricing, a China chapter, a deal database and manufacturing and supply chain
• 10 market-moving developments from 2025 and 2026, SWOT, Porter's Five Forces and strategic recommendations
• 56 company profiles
• Download the Table of Contents (PDF)

Who buys this report

• Biopharma executives and business development teams: size editing opportunities by technology and setting and find partners and acquisition targets.
• Tools and services suppliers: judge demand for guide RNA, enzymes, engineered cells, screening and CDMO services.
• Investors and analysts: model the growth of base, prime and in vivo editing and benchmark deal values.
• Agricultural and animal breeders: plan for gene-edited crops and livestock as regulation changes.

Use independent research that makes you the expert. Your credit card order sends the report to your inbox instantly. Check all your licensing options, but don't worry: your order is available as a credit if you wish to upgrade.

See the Table of Contents. GET the Free Sample of this Report.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.Sc., M.B.A., is the President of Howe Sound Research. His education includes:

Finance for Senior Executives - Harvard Business School

Market Research - Burke Institute

M.B.A. (Finance and Policy) - University of British Columbia

B.Sc. (Chemistry) - University of British Columbia

He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years.